AGENDA

2:00 pm Welcome, Roll Call, Review Agenda and Process
Peter Crooks, MD (Co-Chair)
Kristine Schonder, Pharm D (Co-Chair)
Karen Pace, PhD, MSN, Senior Program Director

2:05 Measures Reviewed on Workgroup Calls and Ready for Full Steering Committee Action

Dialysis Adequacy
- **0247** Hemodialysis Adequacy Clinical Performance Measure I: Hemodialysis Adequacy- Monthly measurement of delivered dose (CMS)
- **0248** Hemodialysis Adequacy Clinical Performance Measure II: Method of Measurement of Delivered Hemodialysis Dose (CMS)
- **0318** Peritoneal Dialysis Adequacy- Delivered Dose of peritoneal dialysis above minimum (CMS) – incorporate concepts from 0253/0254
- **0253** Peritoneal Dialysis Adequacy- Measurement of total Solute Clearance at regular intervals (CMS)
- **0254** Peritoneal Dialysis Adequacy- Calculate Weekly KT/V urea in the Standard Way (CMS)

Mineral Metabolism
- **0255** Measurement of Serum Phosphorus Concentration (CMS)
- **0261** Measurement of Serum Calcium Concentration (CMS)
- **0574** Chronic Kidney Disease (CKD): Monitoring Calcium (IMS Health)
- **0571** Chronic Kidney Disease (CKD): Monitoring Parathyroid Hormone (PTH) (IMS Health)

Patient Education
- **0320** Patient Education Awareness—Physician Level (Kidney Care Quality Alliance)
- **0324** Patient Education Awareness—Facility Level (Kidney Care Quality Alliance)

Vascular Access
- **0256** Hemodialysis Vascular Access- Minimizing use of catheters as Chronic Dialysis Access (CMS)
- **0257** Hemodialysis Vascular Access- Maximizing Placement of Arterial Venous Fistula (AVF) (CMS)
### NATIONAL QUALITY FORUM

<table>
<thead>
<tr>
<th>Time</th>
<th>Section</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15</td>
<td>Follow-up on Measures Reviewed at Meeting</td>
<td><strong>Request for Reconsideration</strong>&lt;br&gt;- 1660 ESRD Patients Receiving Dialysis: Hemoglobin Level &lt;10g/dL (AMA-PCPI)&lt;br&gt;- 1633 Blood Pressure Management (AMA-PCPI)&lt;br&gt;- 1662 Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy (AMA-PCPI)</td>
</tr>
<tr>
<td></td>
<td>Responses to Questions</td>
<td>- 1666 Patients on Erythropoiesis Stimulating Agent (ESA)--Hgb Level &gt; or = 12g/dL (AMA-PCPI)&lt;br&gt;- 1668 Laboratory Testing (Lipid Profile) (AMA-PCPI)&lt;br&gt;- 0627 Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent (Active Health Management)&lt;br&gt;- 0249 Hemodialysis Adequacy Clinical Performance Measure III: Hemodialysis Adequacy--HD Adequacy-- Minimum Delivered Hemodialysis Dose (CMS)&lt;br&gt;- 0323 Hemodialysis Adequacy: Solute (AMA-PCPI)&lt;br&gt;- 0259 Hemodialysis Vascular Access - Decision-making by Surgeon to Maximize Placement of Autogenous Arterial Venous Fistula (Society of Vascular Surgeons)&lt;br&gt;- 0369 Dialysis Facility Risk-adjusted Standardized Mortality Ratio (32) Level (CMS)</td>
</tr>
<tr>
<td></td>
<td>Additional Testing Data</td>
<td>- 0570 Chronic Kidney Disease (CKD): Monitoring Phosphorus (IMS Health) Measure Harmonization&lt;br&gt;- Dialysis adequacy (0249 and 0323)&lt;br&gt;- Others depending on outcome of voting</td>
</tr>
<tr>
<td>3:50</td>
<td>NQF Member and public Comment</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>